OncoSec Medical Inc. (OTCQB: ONCS),
a company developing DNA-based intratumoral cancer immunotherapies, will
present at the 2014 Stifel Healthcare Conference, taking place November
18-19 at the New York Palace Hotel in New York City.
Punit Dhillon, President and CEO, will present a corporate overview of
the Company on Wednesday, November 19, at 4:45 PM EST. At the time of
the presentation, a live webcast will be available via the following
link: http://www.veracast.com/webcasts/stifel/healthcare2014/69214592.cfm
OncoSec recommends registering at least 10 minutes prior to the start of
the presentation to ensure timely access. After the presentation, an
archived version of the webcast will be available in the “Events”
section of the OncoSec web page at http://www.oncosec.com.
About Stifel Healthcare Conference 2014
The Stifel Healthcare Conference will attract top institutional
investors and leading companies in the healthcare sector. The Conference
is designed to provide institutional investors with high-level access to
senior management and industry experts, showcase dynamic emerging
companies, and investigate critical trends that are driving our economy.
For more information, please visit: http://www.stifel.com
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing its
investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec
Medical's core technology is designed to enhance the local delivery and
uptake of DNA IL-12 and other DNA-based immune-targeting agents.
Clinical studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the treatment
of various skin cancers, as well as the potential to initiate a systemic
immune response without the systemic toxicities associated with other
treatments. OncoSec's lead program evaluating ImmunoPulse for the
treatment of metastatic melanoma is currently in Phase 2 development,
and is being conducted in collaboration with several prominent academic
medical centers. As the company continues to evaluate ImmunoPulse in its
current indications, it is also focused on identifying and developing
new immune-targeting agents, investigating additional tumor indications,
and evaluating combination-based immunotherapy approaches. For more
information, please visit www.oncosec.com.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such “forward-looking statements.” Forward-looking statements
are based on management’s current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical’s filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
Copyright Business Wire 2014